These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19204881)

  • 1. World Generic Medicines Congress Americas--a Health Network Communications Conference. 18-21 November 2008, Washington DC, USA.
    Bowman M
    IDrugs; 2009 Feb; 12(2):92-4. PubMed ID: 19204881
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 4. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
    Kuhrt K
    IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 6. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RX for nosebleed prices.
    Greenwald J
    Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
    [No Abstract]   [Full Text] [Related]  

  • 8. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 10. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
    Kuhrt K; Chace-Ortiz M
    IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-18. PubMed ID: 20213921
    [No Abstract]   [Full Text] [Related]  

  • 12. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 13. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 14. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
    Kuhrt K
    IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 16. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 19. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 20. Regulation of biogenerics: a survey of viewpoints.
    Nieminen O; Nordström K
    BioDrugs; 2004; 18(6):399-406. PubMed ID: 15571423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.